Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2
Anant Labs manufacture and furnish high quality Lamivudine impurities for global markets. Our Lamivudine EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
Synonyms
4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-onelamivudine134678-17-4EpivirZeffixEpivir-HBV(-)-2'-Deoxy-3'-thiacytidineGR-109714XVIROLAM(-)-BCH-189GR109714X3'-Thia-2',3'-dideoxycytidineLamivudine teva4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONEbeta-L-2',3'-Dideoxy-3'-thiacytidinebeta-L-3'-Thia-2',3'-dideoxycytidine4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-oneBCH 189, (-)-LamivudinaLamivudinumGR 109714X(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosineBCH1894-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONECHEBI:635774-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one2T8Q726O95NSC-760061(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinoneDTXSID7023194TRIUMEQ COMPONENT LAMIVUDINELAMIVUDINE TEVA PHARMA B.V.TRIZIVIR COMPONENT LAMIVUDINEDELSTRIGO COMPONENT LAMIVUDINE2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINEEpivir HBV2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-lamivudine oral3TC Lamivudine2',3' Dideoxy 3' thiacytidine4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-1,2-dihydropyrimidin-2-one4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2-oneLamivudine, 3TCRefChem:798426J05AF05DTXCID001508532603-844-3Heptovir136891-12-83TCBCH-189HeptodinLamivirCIS-LAMIVUDINE4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one(-)NGPB-21MFCD00869739HepitecZefixHeptivirBCH 189Lamivudine [USAN:BAN:INN](-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine2(1H)-Pyrimidinone,4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-Epivir(TM)HHA & LamivudineLamivudine & GNASMR000466319Epivir (TN)(-)-BCH 189DTHCrac-cis-Lamivudine ((2RS,5SR)-Lamivudine)CHEMBL141HSDB 7155DRG-0126GG-7143TC and NV-01(-)-SddCLamivudeineLamivudine (JAN/USP/INN)3TC & GNA3TC & SSTHHA & 3TC(+/-)-SddCCCRIS 9274Lamivudine RSNSC620753Lamivudine CRSEpivir;UNII-2T8Q726O95BCH-790Lamivudine [USAN:USP:INN:BAN]NCGC00159341-04Lamivudine (Standard)Lamivudine (EPIVIR)CPD000466319LAMIVUDINE [MI](+/-)-3TC(+/-)-BCH-189LAMIVUDINE [INN]LAMIVUDINE [JAN]LAMIVUDINE [HSDB]LAMIVUDINE [USAN]LAMIVUDINE [VANDF]Epitope ID:613392LAMIVUDINE [MART.]2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-LAMIVUDINE [USP-RS]LAMIVUDINE [WHO-DD]LAMIVUDINE [WHO-IP]Lamivudine, cis-(+/-)-US4RZW252LMLS000759424MLS001424097MLS006011910BIDD:GT0033LAMIVUDINE [EMA EPAR]SCHEMBL109675Lamivudine - Bio-X trade markorb1310390orb3141279LAMIVUDINE [EP IMPURITY]LAMIVUDINE [ORANGE BOOK]GTPL12673HY-B0250RLAMIVUDINE [EP MONOGRAPH]KIVEXA COMPONENT LAMIVUDINEGLXC-05058HMS2051D21HMS3259F08HMS3713C16LAMIVUDINE [USP MONOGRAPH]EPZICOM COMPONENT LAMIVUDINELAMIVUDINUM [WHO-IP LATIN]TEMIXYS COMPONENT LAMIVUDINEALBB-038661COMBIVIR COMPONENT LAMIVUDINEHY-B0250MSK10170Lamivudine for system suitability RSBBL033871BDBM50366817EBC-03887s1706SBB066293STK801940lamivudine & TNF-alpha & IFN-gammaAKOS005622556AKOS015854841Lamivudine, >=98% (HPLC), powder(-)-BCH189AC-1416CCG-100984DB00709KS-1073NC00234NC00705NL06295NSC 760061Lamivudine for system suitability 1 CRSNCGC00159341-05NCGC00159341-18NCGC00159341-20BL164607EMTRICITABINE IMPURITY C [WHO-IP]L0217NS00007004SW197614-3C07065D00353EN300-123034Lamivudeine 100 |Ig/mL in Acetonitrile:WaterLamivudine 100 microg/mL in Acetonitrile:WaterP17147AB00639995-06AB00639995-08AB00639995_09F227713Q422631SR-01000759420SR-01000759420-5BRD-K02992638-001-11-8Z1509637175Lamivudine Working Standard (Secondary Reference Standard)Lamivudine, British Pharmacopoeia (BP) Reference StandardLamivudine, European Pharmacopoeia (EP) Reference Standard(2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-Tocis(+/-)-2-Hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolaneLamivudine, United States Pharmacopeia (USP) Reference Standard(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine(-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIRLamivudine, 1.0 mg/mL in methanol, certified reference materialLamivudine, Pharmaceutical Secondary Standard; Certified Reference Material(+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, cis-2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, cis-(+/-)-3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-onecis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinoneLamivudine for system suitability 1, European Pharmacopoeia (EP) Reference StandardLamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standardrel-4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone1117764-41-62(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]
